Straits Times Index
3,410.81 -29.07 (-0.85%) Nikkei
40,912.37 -1.28 (-0.00%) Hang Seng
17,799.61 -228.67 (-1.27%) FTSE 100
8,203.93 -37.33 (-0.45%) Bitcoin USD
56,377.25 +1,819.50 (+3.34%) CMC Crypto 200
1,172.50 -36.20 (-2.99%)
Anixa Biosciences, Inc. (ANIX)
| Previous close | 2.2600 |
| Open | 2.2800 |
| Bid | 1.6200 x 200 |
| Ask | 2.9100 x 200 |
| Day's range | 2.2414 - 2.3260 |
| 52-week range | 2.1500 - 5.1300 |
| Volume | |
| Avg. volume | 82,279 |
| Market cap | 73.295M |
| Beta (5Y monthly) | 0.89 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3700 |
| Earnings date | 04 Jun 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 7.00 |
PR NewswireAnixa Biosciences Treats Sixth Patient in its Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a biotechnology company focused on the treatment and prevention of cancer, today announced that it has treated the sixth patient in the ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. This patient is expected to be the last patient in the second dosage cohort. If there continue to be no adverse effects experienced by the second cohort participants, enrollment of the
- PR Newswire
Anixa Biosciences Commences Treatment of Fifth Patient in Ovarian Cancer CAR-T Clinical Trial
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that treatment has commenced for the fifth patient in its ongoing Phase 1 clinical trial of its novel chimeric antigen receptor T-cell (CAR-T) therapy for ovarian cancer. The study is being conducted through a research partnership with Moffitt Cancer Center.
- PR Newswire
Anixa Biosciences Expands Partnership with Cleveland Clinic to Develop Additional Cancer Vaccines
Anixa Biosciences, Inc. ("Anixa" or the "Company") (NASDAQ: ANIX), a clinical-stage biotechnology company focused on the treatment and prevention of cancer, today announced that it has entered into a joint development agreement with Cleveland Clinic to develop novel vaccines for various cancer types. Cleveland Clinic is currently conducting a Phase 1 clinical trial targeting triple negative breast cancer (TNBC), the most aggressive and lethal form of breast cancer, and an ovarian cancer vaccine
